Macular Degeneration Treatment Market size is poised to witness substantial growth between 2022 and 2028. Emerging aging population across the globe, coupled with the rising number of obese and cardiovascular patients, will fuel the market growth during the forecast timeline. Moreover, the growing population with retinal disorders and hypertension will also lead to growth trends in the industry.
Increasing indulgence in smoking and foods containing saturated fats may lead to macular degeneration and may change the industry outlook in the coming years. Race is also one of the factors causing AMD. As per a study by the Mayo clinic, Caucasian people are commonly affected by these diseases leading to growth in the North American region. Furthermore, growing R&D activities led to developments like the inception of CY-09, an experimental drug to protect the macula from inflammation and could reduce the occurrence of dry AMD will support industry growth in the coming years.
With respect to the disease indication segment, wet AMD is projected to showcase substantial expansion over the forecast timeframe. According to a study by Cleveland Clinic, around 15% of the suffering from AMD have Wet-AMD. Driven by the severity of the disease, several R&D activities like the introduction of biosimilars to treat AMD have made headlines in recent times.
The anti-VEGF segment may contribute appreciably to the market owing to their efficiency in treating Wet-AMD. According to the American Academy of Opthalmology (AAO), these drugs are effective in stabilizing the vision in about 90% of people who take it and further improve the vision in about one-third of patients.
Under the distribution channel segmentation, hospitals are more likely to become the growth drivers. Increased hospital visits after COVID-19 vaccination and reduced cases will foster the demand for treatment among the elderly. Alongside, the diagnosis and treatment of the disease require regular hospital visits spurring the industry trends.
The increasing cardiovascular patients and the majority of the Caucasian population will lead to further expansion. The emerging drug adoption for the treatment of these diseases and growing R&D will push the market share.
Few of the leading players contributing to the market share are Pfizer, Novartis, Ophthotech Corporation, Santen Pharmaceuticals, Neurotech Pharmaceuticals, Bayer, StemCells, Allergan, GlaxoSmithKline, Sanofi, and Valeant Pharmaceuticals. These firms are putting their efforts in growth fueling activities, mergers, collaborations, acquisitions to strengthen their market position and retain customer base.
An example would be the Sanofi’s recent investment of close to USD 60 million in Gyroscope. Presently, GT005, the latter’s lead investigational gene therapy, is being evaluated in Phase II clinical trials for treating age-related macular degeneration (AMD).
The COVID-19 has had a dissenting impact on the market. Travel and movement restriction on the public and the increased risk of infection significantly reduced the number of hospitals and clinical visits. However, the industry is anticipated to reach the pre-pandemic growth rates as AMD clinics are following the COVID safety norms to ensure the safety of patients. It has increased the footfall in the hospitals and clinics and may result in improved growth.
Market, By Disease Indication
Market, By Drug Class
Market, By Distribution Channel
The above information is provided for the following regions and countries: